The Biggest Pharmacogenomics Advances of 2025 — Year in Review
As 2025 comes to a close, pharmacogenomics has firmly stepped out of its former niche and into the spotlight as a research-driven catalyst…
-
-
Pharmacogenomics Is Transforming Drug Development and Patient Care: Insights from a Recent Study
Pharmacogenomics—the study of how an individual’s genetic makeup influences their response to medications—has become one of the most important pillars of modern personalized…
-
Machine Learning for pharmacogenomic variant effect predictions: Insights From a Recent Review
In the last decade, pharmacogenomics (PGx) has moved from a niche research domain into a central pillar of precision medicine. Sequencing is now…
-
FDA’s Final Rule on Laboratory-Developed Tests: Implications for Pharmacogenomics
In May 2024, the U.S. Food and Drug Administration (FDA) published a final rule that would bring laboratory-developed tests (LDTs) explicitly under the…
-
What You Should Know About Pharmacogenomic Variant Annotation
The promise of precision medicine lies in its ability to tailor treatments to the genetic makeup of each patient. Pharmacogenomics is central to…
-
Pharmacogenomic Data Submission: Guidelines for Clinicians and Industry Professionals
This blog provides a comprehensive overview of the FDA’s current and draft guidance on pharmacogenomic data submission, highlighting key regulatory requirements, submission algorithms, voluntary submissions, and practical considerations for clinicians and industry professionals.
-
Overcoming Barriers to Implementing PGx Testing in Routine Care
Learn about the barriers to Implementing PGx Testing
-
Polygenic Scores (PGS): A Complete Guide to the Future of Predictive Genomics
In this guide, we’ll explore what PGS are, how they are built, the value they bring to healthcare, and the challenges that come with them. We’ll then look at how they connect to pharmacogenomics—a field that uses genetics to tailor medication—and why learning both will be key for the future of medicine.
-
Are Prescribers Aware of the Liability Associated With Ignoring PGx FDA Recommendations for Commonly Used Medications?
Dr. Patricia Cammazola doesn’t think so. “Physicians/prescribers are often not aware of the liability associated with not considering PGx FDA recommendations and CPIC…
-
Guarding Against Chemotherapy Toxicity: The Promise of Helix’s DPYD Test
The key lies in the DPYD gene, which produces an enzyme called DPD that helps the body break down and clear fluoropyrimidines.
End of content
End of content